title: Targeting α7 Nicotinic Acetylcholine Receptor to Combat Inflammation in Cardio-Cerebral-Vascular Diseases.
abstract: BACKGROUND
  Cardio-cerebral-vascular diseases, including myocardial infarction, atherosclerosis, hypertension, and stroke etc, are the major reasons for morbidity and mortality all over the world. Recent studies showed that inflammation exerts an important impact on the pathogenesis and development of cardio-cerebral-vascular diseases. "The cholinergic anti-inflammatory pathway", mainly modulated through α7 nicotinic acetylcholine receptor (α7nAChR), has attracted much attention.
  
  
  OBJECTIVE
  The purpose of this review was to discuss the role of α7nAChR during the pathological processes in myocardial infarction, atherosclerosis, hypertension and stroke.
  
  
  RESULTS
  Most of the existing literatures involved in studying on myocardial infarction, atherosclerosis, hypertension and stroke showed that activation of α7nAChR might be a potential strategy for the prevention and treatment of these diseases.
  
  
  CONCLUSIONS
  Targeting α7nAChR to combat inflammation might be a novel therapy in cardiocerebral- vascular diseases.
authors: Department of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai 200433, China.
authors: Hui
authors: H
authors: Fu
authors: Department of Pharmacy, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, China.
authors: Min
authors: M
authors: Ni
authors: Department of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai 200433, China.
authors: Ji-Kuai
authors: JK
authors: Chen
authors: Department of Pharmacy, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, China.
authors: Ting
authors: T
authors: Zhao
authors: Department of Pharmacy, Zhejiang Xiaoshan Hospital, Zhejiang 311202, China.
authors: Ya-Ping
authors: YP
authors: Deng
authors: Department of Pharmacy, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, China.
authors: Dong-Jie
authors: DJ
authors: Li
authors: Department of Pharmacy, Zhejiang Xiaoshan Hospital, Zhejiang 311202, China.
authors: Guo-Jun
authors: GJ
authors: Jiang
authors: Department of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai 200433, China.|Department of Pharmacy, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, China.
authors: Fu-Ming
authors: FM
authors: Shen
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use*; D050197:Atherosclerosis / Q000188:drug therapy / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000378:metabolism; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000378:metabolism; D004195:Disease Models, Animal; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000378:metabolism; D058990:Molecular Targeted Therapy; D009203:Myocardial Infarction / Q000188:drug therapy / Q000378:metabolism; D020521:Stroke / Q000188:drug therapy / Q000378:metabolism; D064569:alpha7 Nicotinic Acetylcholine Receptor / Q000819:agonists*
chemical_list: D000893:Anti-Inflammatory Agents; D064569:alpha7 Nicotinic Acetylcholine Receptor
keywords: anti-inflammation target; cardio-cerebral-vascular diseases; hypertension; inflammation; myocardial infarction; α7nAChR